Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
Oncoimmunology, 2017•Taylor & Francis
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening
side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic
lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids
off-target side effects such as activation of regulatory T cells and vascular endothelium.
side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic
lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids
off-target side effects such as activation of regulatory T cells and vascular endothelium.
Abstract
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.
Taylor & Francis Online